Spero Therapeutics, Inc. (SPRO)
SPRO Stock Price Chart
Explore Spero Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SPRO price movements and trends.
SPRO Company Profile
Discover essential business fundamentals and corporate details for Spero Therapeutics, Inc. (SPRO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Nov 2017
Employees
32.00
Website
https://sperotherapeutics.comCEO
Esther Rajavelu
Description
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
SPRO Financial Timeline
Browse a chronological timeline of Spero Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.17, while revenue estimate is $281.95k.
Earnings released on 13 May 2026
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $258.00k , meeting expectations.
Earnings released on 26 Mar 2026
EPS came in at $0.53 surpassing the estimated -$0.20 by +365.00%, while revenue for the quarter reached $41.30m , beating expectations by +58.83%.
Earnings released on 13 Nov 2025
EPS came in at -$0.13 surpassing the estimated -$0.25 by +48.00%, while revenue for the quarter reached $3.05m , missing expectations by -74.60%.
Earnings released on 12 Aug 2025
EPS came in at -$0.03 surpassing the estimated -$0.38 by +92.11%, while revenue for the quarter reached $11.80m , beating expectations by +7.29%.
Earnings released on 13 May 2025
EPS came in at -$0.25 surpassing the estimated -$0.55 by +54.55%, while revenue for the quarter reached $5.87m , missing expectations by -46.60%.
Earnings released on 27 Mar 2025
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%, while revenue for the quarter reached $9.36m , beating expectations by +50.90%.
Earnings released on 14 Nov 2024
EPS came in at -$0.32 falling short of the estimated -$0.27 by -18.52%, while revenue for the quarter reached $13.47m , beating expectations by +225.86%.
Earnings released on 5 Aug 2024
EPS came in at -$0.33 surpassing the estimated -$0.35 by +5.71%, while revenue for the quarter reached $6.02m , beating expectations by +22.80%.
Earnings released on 15 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.07 by -242.86%, while revenue for the quarter reached $4.20m , missing expectations by -80.47%.
Earnings released on 13 Mar 2024
EPS came in at $0.96 surpassing the estimated -$0.10 by +1.06k%, while revenue for the quarter reached $71.83m , beating expectations by +285.54%.
Earnings released on 13 Nov 2023
EPS came in at $0.02 surpassing the estimated -$0.15 by +113.33%, while revenue for the quarter reached $25.47m , missing expectations by -4.34%.
Earnings released on 10 Aug 2023
EPS came in at -$0.23 surpassing the estimated -$0.29 by +20.69%, while revenue for the quarter reached $788.00k , missing expectations by -92.86%.
Earnings released on 11 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.35 by +28.57%, while revenue for the quarter reached $740.00k , missing expectations by -26.00%.
Earnings released on 30 Mar 2023
EPS came in at $0.55 surpassing the estimated $0.04 by +1.17k%, while revenue for the quarter reached $46.30m , beating expectations by +102.46%.
Earnings released on 14 Nov 2022
EPS came in at -$0.33 surpassing the estimated -$0.34 by +2.94%, while revenue for the quarter reached $1.08m , missing expectations by -80.02%.
Earnings released on 10 Aug 2022
EPS came in at -$0.87 surpassing the estimated -$0.88 by +1.14%, while revenue for the quarter reached $896.00k , missing expectations by -37.49%.
Earnings released on 16 May 2022
EPS came in at -$1.01 falling short of the estimated -$0.87 by -16.09%, while revenue for the quarter reached $247.00k , missing expectations by -87.17%.
Earnings released on 31 Mar 2022
EPS came in at -$0.90 falling short of the estimated -$0.80 by -12.50%, while revenue for the quarter reached $2.74m , missing expectations by -44.57%.
Earnings released on 10 Nov 2021
EPS came in at -$0.70 matching the estimated -$0.70, while revenue for the quarter reached $3.06m , meeting expectations.
Earnings released on 5 Aug 2021
EPS came in at -$0.63 surpassing the estimated -$0.77 by +18.18%, while revenue for the quarter reached $5.15m , meeting expectations.
SPRO Stock Performance
Access detailed SPRO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
